Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents



Mesoblast’s Ryoncil is scheduled for a full FDA review in September, but first it will face an advisory committee’s questions. (Getty)
https://www.fiercepharma.com/manufacturing/mesoblast-faces-fda-committee-pushback-over-cell-therapy-manufacturing-clinical-data

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.